These alterations were either predictively pathogenic or located in the catalytic region, suggesting a potential impact of ALK mutations on the sensitivity to crizotinib, as previously described in various tumor types (e.g., NSCLC, anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor) [43,44,45]. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.